5-Fluorouracil is converted inside cells to 5-fluro-deoxyuridine monophosphate which inhibits thymidylate synthase and disrupts DNA synthesis. A 2-year-old male was admitted to the hospital with non-metastatic hepatoblastoma and underwent CT scanning showing mild hepatomegaly and a patent portal vein. Due to bone marrow suppression from treatment, the patient experienced neutropenia, thrombocytopenia, nausea, vomiting, and diarrhea.

1. DEPARTMENT OF PHARMACOLOGY
FACULTY OF PHARMACY
CAIRO UNIVERSITY
NUMBERS 40684-40700 1

2.  5-Fluorouracil is a uracil with a stable fluorine atom
at position 5
 When inside the cell, it’s converted to the
corresponding deoxynucleotide (5-fluro-
deoxyuridine monophosphate [5-FdUMP])
2

3. • A 2 years old male was admitted to 57357
hospital with non metastatic
hepatoblastoma
• Associated Diagnosis: None.
• Fair General condition and Huge hepatic
mass.
3

4. Treatment Day II
CT scanning of the pelvis and the abdomen:
Mild hepatomegaly.
The main portal vein is patent.
4

5. CBC
5

6. • Due to bone marrow suppression, there
is notable:
Neutropenia.
Thrombocytopenia.
6

7. NAUSEA
VOMITING DIARRHOEA
Other associated side effects
7

8. Stomatitis and irritation of
the GI mucosa.
8

9. The hand-foot syndrome
CHARACTERIZED BY REDDENING,
SWELLING, NUMBNESS AND
DESQUAMATION OF THE SKIN.
9

10. Other unreported side effects
• CARDIOTOXICITY ( ARRHYTHMIA OR ANGINA ).
• NEPHROTOXICITY.
• BLURRED VISION.
10

11. • 57357 HOSPITAL PHARMACY.
• LEXI.COM
• KATZUNG BASIC AND CLINICAL PHARMACOLOGY 12TH EDITIO
11

12. 12